Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Share-based Compensation (2023 - 2025)

NewAmsterdam Pharma's Share-based Compensation history spans 3 years, with the latest figure at $14.0 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 48.94% year-over-year to $14.0 million; the TTM value through Dec 2025 reached $59.4 million, up 76.76%, while the annual FY2025 figure was $59.4 million, 76.76% up from the prior year.
  • Share-based Compensation for Q4 2025 was $14.0 million at NewAmsterdam Pharma, down from $15.0 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $15.2 million in Q1 2025 and bottomed at $5.4 million in Q3 2023.
  • The 3-year median for Share-based Compensation is $8.1 million (2024), against an average of $9.8 million.
  • The largest annual shift saw Share-based Compensation increased 3.97% in 2024 before it soared 92.13% in 2025.
  • A 3-year view of Share-based Compensation shows it stood at $6.0 million in 2023, then surged by 56.76% to $9.4 million in 2024, then skyrocketed by 48.94% to $14.0 million in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Share-based Compensation are $14.0 million (Q4 2025), $15.0 million (Q3 2025), and $15.2 million (Q2 2025).